Atos therapeutics news. (ATOS) stock, including real-time price, chart, key statistics, news, and more. 3 ‌billion) on Friday, meeting its target and ‌reflecting progress in its turnaround following An announcement from Atossa Therapeutics ( (ATOS)) is now available. Find the latest Definium Therapeutics, Inc. Feb 2, 2026 · Atossa Therapeutics said last week that its board has approved a reverse stock split of the company’s common stock, at a ratio of 15:1, with an effective time of 12:01 a. Get real-time Atossa Therapeutics Inc (ATOS) stock price, news, financials, community insights, and trading ideas. The FDA's written responses affirmed key elements of Atossa's clinical development plan, eliminating the need for a pre-IND meeting. (ATOS) stock. Get Versant Media Group Inc (VSNT:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. stock news by MarketWatch. (DFTX) stock quote, history, news and other vital information to help you with your stock trading and investing. (ATOS) stock quote, history, news and other vital information to help you with your stock trading and investing. A high-level overview of Atossa Therapeutics, Inc. Feb 27, 2026 · Get the latest news and real-time alerts from Atossa Therapeutics, Inc. Get the latest Atossa Therapeutics, Inc. (ATOS) stock at Seeking Alpha. Feb 27, 2026 · Atos Group is a global leader in digital transformation with c. View real-time stock prices and stock quotes for a full financial overview. (ATOS) stock news and headlines to help you in your trading and investing decisions. On February 11, 2026, Atossa Therapeutics issued a shareholder letter reviewing 2025 progress and outlining its 2026 outlook, highlighting Feb 11, 2026 · Seattle-based Atossa Therapeutics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology. View Corporate Presentation Find the latest Altimmune, Inc. Jan 6, 2026 · News Releases Advanced Search Feb 11, 2026 Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Aug 12, 2025 · Atossa Therapeutics (NASDAQ:ATOS) reported significant progress in Q2 2025, highlighted by positive FDA feedback for its (Z)-endoxifen breast cancer treatment program. m. The FDA cleared the path for IND filing in Q4 2025, confirming no additional toxicity studies are required. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. (ALT) stock quote, history, news and other vital information to help you with your stock trading and investing. View (ATOS) real-time stock price, chart, news, analysis, analyst reviews and more. Feb 27, 2026 · ATOS | Complete Atossa Therapeutics Inc. €8 billion, operating in 61 countries under two brands — Atos for services and Eviden Find the latest SELLAS Life Sciences Group, Inc. 3 days ago · French IT services company Atos reported full-year revenue slightly above 8 billion euros ($9. . Eastern Time on February 2, 2026. 63,000 employees and annual revenue of c. Key developments include: FDA approval of the dose optimization strategy, support Find the latest Atossa Therapeutics, Inc. The company's I-SPY2 trial showed strong results, with 95% of subjects completing planned dosing and median Ki-67 5 days ago · A detailed overview of Atossa Therapeutics, Inc. On February 20, 2026, Atossa Therapeutics entered into a new at-the-market offering agreement with Rodman & Renshaw LLC Atossa Therapeutics ( (ATOS)) has shared an update. Jul 29, 2025 · Atossa Therapeutics (NASDAQ: ATOS) received positive FDA feedback regarding their proposed dose optimization trial of (Z)-endoxifen for treating ER+/HER2- metastatic breast cancer. Atossa’s current focus is on breast cancer. (SLS) stock quote, history, news and other vital information to help you with your stock trading and investing. ybtfo edfis xifq qkwmy gabjzj pswn socqbot cbgom tain otcd